Showing 4211-4220 of 8878 results for "".
- Almirall Launches New Campaign, Atopic Museum for World Eczema Dayhttps://practicaldermatology.com/news/almirall-launches-new-campaign-atopic-museum-for-world-eczema-day/2462003/Almirall unveiled its atopic dermatitis awareness campaign "Moving aheAD" for World Atopic Eczema Day. The campaign includes the “Atopic M
- Arcutis Submits NDA for Roflumilast Cream 0.15% for AD Treatmenthttps://practicaldermatology.com/news/arcutis-submits-nda-for-roflumilast-cream-015-for-ad-treatment/2462001/Arcutis Biotherapeutics, Inc. submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older. Roflumilast cream is
- One to Watch: Nektar Therapeutics' Rezpegaldesleukin Shows Promise in Phase 1b AD Studyhttps://practicaldermatology.com/news/one-to-watch-nektar-therapeutics-rezpegaldesleukin-shows-promise-in-phase-1b-ad-study/2462000/Nektar Therapeutics’ rezpegaldesleukin met several clinical efficacy endpoints with statistically significance, including Body Surface Area (BSA), Dermatology Life (DLQI), and Patient-Oriented Eczema Measure (POEM) in addition to reported efficacy for Eczema Area and Severity
- Innovation in Action: A Newly Developed Anti-bacterial Silver Gel May Best Other Silver-based Drugshttps://practicaldermatology.com/news/innovation-in-action-a-newly-developed-anti-bacterial-silver-gel-may-best-other-silver-based-drugs/2461999/A new anti-bacterial gel based on silver and sulfur-containing amino acids may be one hundred times more effective than other silver-based antibacterials, according to research in the Journal of Material
- Cetaphil Takes on Aging Skin with New Skincare Linehttps://practicaldermatology.com/news/cetaphil-takes-on-aging-skin-with-new-skincare-line/2461995/Galderma is rolling out Cetaphil Healthy Renew, its first-ever healthy aging skincare line. "Aging skin is a particular point of frustration for my sensitive skin patients due to increased risks of irritation and an already compromised skin barrier,” says Cetaphil partn
- Hillstream Enters Into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritishttps://practicaldermatology.com/news/hillstream-enters-into-an-exclusive-option-agreement-to-acquire-a-clinical-stage-asset-for-chronic-pruritis/2461994/Hillstream BioPharma, Inc. is set to acquire AV104 for chronic pruritis. AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis. The Company intends to first seek approval in an orphan disease for the treatment of mode
- ABMS Announces Class of 2023-2024 Visiting Scholarshttps://practicaldermatology.com/news/abms-announces-class-of-2023-2024-visiting-scholars/2461993/Gillian Heinecke, MD, an assistant clinical professor at SSM Health/Saint Louis University in St. Louis, Mo. is the American Board of Dermatology’s 2023-2024 Visiting Scholar. The American Board of Medical Specialties (ABMS) selected thirteen outstanding indivi
- DermTech Appoints Mark Aguillard as Chief Commercial Officerhttps://practicaldermatology.com/news/dermtech-appoints-mark-aguillard-as-chief-commercial-officer/2461990/Mark Aguillard is DermTech, Inc.’s chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech’s overall commercial strategy and execution. Prior to joining is DermTech, Mr. Aguillard served as the chief commercial officer of Epic
- Interim INTEGUMENT-OLE Results: Arcutis’ Roflumilast Cream 0.15% Performs Well in ADhttps://practicaldermatology.com/news/arcutis-roflumilast-cream-015-performs-well-in-ad/2461987/Roflumilast cream 0.15% showed durable and improved efficacy over time and a favorable safety profile in mild to moderate Atopic Dermatitis (AD), according to interim results from the INTEGUMENT-OLE long-term open-label study. Arcutis intends to submit a supplemental New Drug Applicatio
- Hoth's Steroid-sparing AD Treatment Shows Promise in Phase 1b Trialhttps://practicaldermatology.com/news/steroid-sparing-ad-treatment-shows-promise-in-phase-1b-trial/2461984/BioLexa led to a 35% improvement in SCORAD ("SCORing Atopic Dermatitis") measurement and a 60% improvement in EASI (Eczema Area and Severity Index) measurement of atopic skin disease during a 14-day treatment period, whereas gentamicin lotion and placebo had no effect, accordi